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1. Summary 
 
Background.  Arginine vasopressin (AVP) is a key hormone in regulating blood 
pressure and body water balance, but despite modern procedures remains difficult to 
measure. Copeptin, the carboxyl-terminus portion of the AVP precursor, is much 
more stable and presents a reliable alternative to measuring the secretion of AVP. 
Copeptin has been studied to great extent in adults and is emerging as a useful 
diagnostic and prognostic biomarker for a variety of diseases. As of now there has 
been no research on copeptin in pediatric medicine. The aim of this study was to 
assess the normal basal values of plasma copeptin in infants in the first days of life 
and to investigate influencing factors at birth and during early postnatal adaptation. 
 
Methods.  A prospective cross-sectional study was carried out at Zurich University 
Hospital and included 177 infants born between 32 and 41 weeks of gestation. Blood 
samples were obtained from the umbilical artery and the umbilical vein at birth and 
again from venous puncture at day 3 of life. The collected samples were prepared 
and then analyzed for their copeptin content using the CT-proAVP luminescence 
immunoassay (B.R.A.H.M.S Company, Hennigsdorf, Germany). 
 
Results.  One hundred seventeen paired blood samples were collected from 
umbilical arteries and veins, along with an additional twenty-six unpaired venous cord 
blood samples. Copeptin in the umbilical artery was consistently higher than in the 
umbilical vein (median 18.2 [range 2.38-5000] pmol/L vs. 10.2 [1.87-5000] pmol/L) 
and there was a strong relationship between these values (Spearman’s rank 
correlation coefficient (Rs)=0.825, p<0.001). Overall, copeptin levels at birth were 
much higher after vaginal delivery compared to after caesarean section. Furthermore, 
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the copeptin concentrations in arterial and venous umbilical cord plasma correlated 
significantly with both the pH value (Rs=-0.639, Rs=-0.578, both p<0.001, 
respectively) and the base excess (Rs=-0.645, Rs=-0.638, both p<0.001, respectively) 
in the umbilical artery. 
One hundred and two venous blood samples were collected at day 3 of life (of which 
sixty-eight having a paired venous sample from birth). Average plasma copeptin 
levels at day 3 of life were similar to those at birth, but the distribution of values was 
much smaller in comparison (median 13.5 [range 4.63-169] pmol/L). Finally, plasma 
copeptin concentrations at day 3 of life were directly correlated to the maximal 
postnatal weight loss experienced by the infant (Rs=0.438, p<0.001), which in turn 
was inversely correlated to copeptin concentrations at birth in the umbilical artery and 
vein (Rs=-0.309, Rs=-0.289, both p=0.001, respectively). 
 
Conclusion.  Exceptionally high copeptin values were related to vaginal delivery and 
birth acidosis in healthy newborns. Copeptin release at birth is therefore likely 
brought on by birth stress. Plasma copeptin concentrations at day 3 of life provided 
insight to the actual water balance of the infant, which was less negative in infants 
who experienced a larger copeptin release at birth. The results from this study put 
forward important functions of AVP in primary and secondary adaptation in newborns 
and attest a role of copeptin measurement at birth in detecting fetal distress, 
particularly perinatal asphyxia. 
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2. Background 
 
Vasopressin: Biochemical Properties and Function 
Arginine vasopressin (AVP), also referred to as antidiuretic hormone (ADH), is a 
nonapeptide hormone produced mainly by AVP-specific magnicellular neurons in the 
supraoptic nuclei (SON) and the paraventricular nuclei (PVN) of the hypothalamus, 
whose axons project down to make up the posterior pituitary gland 1. Another group 
of AVP-producing neurons is located in the suprachiasmatic nucleus 2. AVP derives 
from a larger precursor protein, pre-provasopressin (pre-proAVP), which consists of 
four segments: a signal peptide, AVP itself, neurophysin II and copeptin 3. After 
translation, pre-proAVP is packaged into vesicles and transported to the 
neurohypophysis axon endings 4, undergoing various enzymatic modifications on the 
way before finally being cleaved into its individual components 3. Appropriate 
stimulation of vasopressinergic neurons creates an action potential, which provokes a 
fusion of the neurosecretory vesicles with the cell membrane of the axon endings 5, 
releasing the peptides in equimolar concentrations 6 into the bloodstream where they 
circulate independently from one another 3. The same stimulation also increases the 
rate of transcription 7 and upgrades the axonal transport of the neurosecretory 
vesicles 4. The elimination of AVP from circulation is ensured mainly by renal but also 
hepatic clearance 8,9. 
A variety of stimuli, mainly changes in plasma osmolality and in the pressure-volume 
system, account for AVP release (Figure 1). Osmotic stimuli are perceived by 
osmoreceptors in different regions of the brain 10. There is a positive linear 
relationship between plasma osmolality and basal plasma AVP in healthy persons 11. 
The osmoreceptors are under a constant mild stimulation but are very sensitive to 
change, where even the slightest increase in plasma osmolality causes an increase 
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in plasma AVP levels 11. Changes in blood pressure or volume are detected by high-
pressure arterial baroreceptors and low-pressure atrial volume receptors 12. These 
changes, however, must be of a certain magnitude in order to bring out an AVP 
release: only a sufficient decrease in either provokes an increase in plasma AVP 11,12. 
Other relevant stimuli for AVP release are nausea and hypoglycemia 13,14. 
The hormone operates in the periphery by binding to either one of three G protein-
coupled AVP receptors on target cells: the V1a, V1b and V2 receptors 15. V2 
receptors are located predominantly on the basolateral membrane of cells of 
connecting tubules and collecting ducts in the nephron. AVP binding results in the 
insertion of previously stored aquaporin 2 water channels into the apical cell 
membrane and in an increased aquaporin 2 synthesis, allowing greater water 
reabsorption by the kidney 15 (Figure 1). V1a receptors are found primarily on smooth 
muscle cells of blood vessels and provoke vasoconstriction from higher plasma AVP 
concentrations 15 (Figure 1). V1b receptors found on the corticotropic cells of the 
anterior pituitary gland are involved in the secretion of adrenocorticotropic hormone 15 
and thus in the hypothalamic-pituitary-adrenal axis stress response 16,17. Interestingly, 
AVP receptors have also been found in the brain 18,19. This direct presence of AVP in 
the central nervous system is likely relevant for many central functions, such as 
social behavior, learning and memory processes, and central temperature and 
cardiovascular regulation 20. 
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Figure 1: Overview on vasopressin regulation 
 
 
 
 
 
 
 
 
 
 
AVP is involved in numerous pathologies. Diabetes insipidus (DI), the clinical 
presentation of a reduced effect of AVP, is brought on either by decreased AVP 
production by the hypothalamus (central DI) or by AVP resistance in the kidney 
(nephrogenic DI). Its main feature is an excessive and diluted urine production 21. 
The Syndrome of Inappropriate Antidiuresis (SIADH) is characterized by an 
increased, non-physiological AVP activity and results in hyponatremia and the 
production of inappropriately concentrated urine 21. In the presence of early 
vasodilatory septic as well as cardiogenic shock plasma AVP levels are higher than 
normal 22,23, and subsequent AVP administration improves hemodynamic parameters 
in these shock states 24,25. Today, AVP is also considered a reasonable first-line 
vasopressor in advanced cardiac life support, although the benefit remains 
questionable 26,27. Lastly, clinical observations indicate an involvement of AVP in the 
pathogenesis of heart failure and liver disease 28,29. 
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Vasopressin in Children 
During human ontogenesis, AVP immunoreactive cells can be detected in the SON 
and the PVN at as early as eighteen weeks of gestation 30. The expression of AVP 
mRNA begins in the second trimester and average levels of the hormone in the 
hypothalamus and pituitary gland then increase with fetal age until birth 30,31. 
Furthermore, there is evidence from animal studies that AVP expression through 
osmotic stimulation is already functional during the fetal period 32,33. At birth, human 
AVP synthesis and secretion is intact. Average AVP concentrations in umbilical cord 
blood plasma are greater than average plasma concentrations measured in adults, 
and depending on the mode of delivery can reach very high levels 34,35. “High AVP 
concentrations in cord blood are associated with higher blood pressure and lower 
skin temperature, indicating peripheral vasoconstriction” and a fully functional 
hormone 36. Plasma AVP levels then decline after birth and normal basal AVP in 
healthy children above one year of age does not differ from healthy adults and 
similarly does not correlate with age 37,38. The necessary osmotic stimuli for secretion 
are the same: plasma AVP concentrations in children correlate significantly with 
plasma and urine osmolality 37. 
Just as in adults, AVP is secondarily involved in the pediatric endocrine response to 
several hemodynamic disorders. Circulating AVP levels are elevated in septic 
children 39. In managing refractory hypotension due to either septic or vasodilatory 
and cardiogenic shock after heart surgery, AVP is an effectively proven vasopressor 
40–42. Its current role in pediatric cardiac arrest, however, is still undetermined 43. 
 
Vasopressin Measurement 
Circulating AVP is generally measured with a radioimmunoassay involving specific 
AVP antiserum 11. Precise measurement is ensured by the high sensitivity and 
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specificity of this test; however, it is challenging to obtain accurate results. In vivo, 
AVP is quickly degraded resulting in a half-life of a few minutes 8 and remains 
unstable even once collected in tubes with or without a matrix, for example EDTA 11. 
This necessitates fast, yet impractical measurement. Although it does not bind to 
plasma proteins 8, circulating AVP does indeed bind to platelets 44. Exact sample 
preparation is therefore required to “avoid contamination of plasma with platelet-
bound AVP” and otherwise falsely representative levels 38. Finally, test samples must 
be modified before analysis with a series of complicated steps 11,45. 
For these reasons routine measurement of AVP has little clinical relevance, even for 
diagnosing AVP dysfunction. Diabetes insipidus is usually diagnosed by performing a 
water deprivation test in which urine and plasma osmolality are measured rather than 
AVP; the latter is reserved for when there is diagnostic doubt 21. For SIADH, elevated 
blood AVP concentrations are not essential diagnostic criteria 21. 
 
Copeptin: An Adequate Marker for Vasopressin 
As introduced above, copeptin is the carboxyl-terminus of pre-proAVP and is 
released together with AVP in equimolar concentrations (Figure 2). It is unclear 
whether it has a concrete function in the periphery, but it is probably involved in pre-
hormone assembly 46. Unlike AVP, copeptin measurement is less troublesome. A 
highly sensitive chemiluminescence sandwich immunoassay for copeptin allows 
precise measurement, having many advantages over the AVP radioimmunoassay 45. 
Results are available after only a few hours, no preanalytical procedures are required 
and sample quantities of as little as 50 μL plasma suffice 47. Contrary to AVP, 
copeptin is considerably stable once collected, especially in EDTA-plasma 45. Sample 
storage here is permitted for up to 14 days at room temperature with virtually no 
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change in the resulting mean measured value compared to the original value 45. The 
same applies to storage at 4° C 45.  
Seeing that copeptin is produced and released along with AVP in equimolar 
concentrations, measurement of circulating copeptin presents a less complicated yet 
reliable means of indirectly measuring AVP (Figure 2). There is a documented 
significant correlation between normal plasma copeptin and normal plasma AVP in 
healthy adults 45. Moreover, copeptin mirrors AVP secretion in the presence of its 
physiological stimuli. Plasma copeptin levels correlate with plasma osmolality in 
healthy subjects 48, and water intake and deprivation result in a decrease and 
increase in copeptin, respectively 45,48. As expected, copeptin also reacts to changes 
in blood volume and pressure. In an animal model, baboons exposed to bleeding 
responded with increases in their plasma copeptin concentrations according to the 
degree of blood loss and hypotension; after reperfusion, the copeptin levels then 
slowly declined 49. In man, a similar response can be observed: a decrease in mean 
arterial blood pressure due to septic shock leads to proportionally increased plasma 
copeptin concentrations 49. 
The ability to mirror AVP secretion is not lost under pathological conditions. With the 
case of primary AVP dysfunction, copeptin levels are pathologically low in patients 
with central DI 50. Moreover, in one study, plasma copeptin concentrations in adults 
presenting with Systemic inflammatory response syndrome (SIRS), sepsis or after 
cardiac surgery were investigated and compared with their corresponding plasma 
AVP concentrations: the resulting mean copeptin values were consistently elevated, 
and here too a significant correlation between copeptin and AVP was observed 51. 
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Figure 2: Overview on vasopressin and copeptin synthesis and function 
                
 
 
 
 
 
 
 
Copeptin: Role in Disease and as a Biomarker 
As previously mentioned, critical illness is characterized by significantly elevated 
plasma copeptin concentrations 51, which increase with ascending degree of illness 
49. Furthermore, it has been shown that average copeptin values are higher in 
nonsurvivors of sepsis or septic shock than in survivors 49. Myocardial infarction is 
also associated with elevated plasma copeptin levels 52. According to one study, the 
combination of copeptin and standard troponin T measurement improved early 
diagnosis after the onset of typical symptoms of acute coronary syndrome 53. In 
addition, copeptin is a possible prognostic biomarker with regards to mortality in the 
days following an acute myocardial infarction as well as for the imminent 
development of heart failure 52,54. Plasma copeptin is also elevated in pulmonary 
disease, and is being investigated as a possible prognostic biomarker for clinical 
outcome in affected patients 55,56. Lastly, there is an association between copeptin 
and stroke. In the case of acute intracerebral hemorrhage, copeptin again correlates 
with the severity of illness and further acts as a prognostic biomarker: patients with 
higher plasma copeptin concentrations on admission have a higher risk of early 
mortality and/or unfavorable functional outcome 57. Similarly, copeptin appears to be 
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an “independent predictor of functional outcome and death” in patients with acute 
ischemic stroke 58. 
The use of this novel and seemingly valuable biomarker in pediatric medicine has 
been hindered thus far by the lack of data available in this field. This study aimed to 
alter this dilemma. 
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3. Methods & Materials 
 
A prospective cross-sectional study was conducted from July 2009 to September 
2009 in the maternity and neonatology wards of Zurich University Hospital and was 
approved by the ethics committee of the hospital (Kantonale Ethikkommission Zürich, 
KEK 08/09). The participating expectant mothers gave written informed consent upon 
admission. 
Details of pregnancy (presence or absence of preeclampsia, diabetes, infection, 
preterm labor or administration of betamethasone for fetal lung maturation), delivery 
(umbilical artery pH, umbilical artery base excess and hematocrit; amount of maternal 
blood loss) and the infants’ birth characteristics (gestational age, birth weight, 
APGAR scores at 5 and 10 minutes) were collected from the charts. Data on the 
infants’ health after birth, whether the infants were exclusively breast fed, additionally 
fed with formula or given intravenous fluid, and the daily weight control were recorded 
by the staff on the maternity or neonatology wards. 
Up to a maximum of three blood samples was collected per infant. The first and 
second of the three samples were drawn immediately after birth, one from the 
umbilical cord artery and one from the umbilical cord vein. The last of the three 
samples contained venous blood drawn from the back of the hand or foot after 64-96 
hours of life, referred to as day 3 of life. 
Approximately 0.3-0.5 ml of blood was drawn per sample and held in EDTA tubes. 
These were immediately placed at 4° C and stored for a maximum of four hours. 
Centrifugation was done at 3220 G for two minutes, after which the supernatant 
containing EDTA-plasma was displaced into a new EDTA tube that was promptly 
stored at -28° C until analysis. 
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Copeptin measurement was performed using the CT-proAVP luminescence 
immunoassay, which was provided and realized by the B.R.A.H.M.S Company 
(Hennigsdorf, Germany). Briefly, three peptides representing three distinct 
sequences positioned on copeptin were chemically synthesized 45. Antibodies 
directed against these peptides were created by immunizing sheep with each 
individual peptide and obtaining their antisera 45. One purified antibody was labeled 
with MACN-Akridinium-NHS-Ester and diluted into assay buffer to produce the tracer 
45. Polystyrene tubes were coated with one of the other purified antibodies 45. The 
last of the three antibodies was diluted in horse serum and used as a calibrator 45. 
Fifty microliters of plasma samples/calibrators were incubated with 200 µL of tracer 
“in the coated tubes under agitation for two hours at room temperature”, the tubes 
were consequently “washed four times…and the bound chemiluminescence was 
measured for one second per tube with a luminometer” 45. The lower detection limit 
was determined at 1.7 pmol/L and the upper detection limit at 5000 pmol/L 45. 
Statistical analysis was performed with the SPSS Statistics program, PASW 18.0 
(SPSS inc., Chicago, Ill.). Specifically, strictly non-parametric tests were applied; 
comparisons of non-parametric data were done using the Wilcoxon signed-rank test 
for paired samples, and the Mann-Whitney U and Kruskal-Wallis tests for 
independent groups. Correlation was determined with the Spearman’s rank 
correlation test. The level of significance was set at p<0.05. 
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4. Results 
 
A total of 362 samples were collected from 177 infants. One hundred seventeen 
blood samples were collected from the umbilical artery, all of which had a 
corresponding paired sample from the umbilical vein. An additional 26 venous cord 
blood samples were further collected. One hundred and two venous blood samples 
were collected at day 3 of life, sixty-eight of which having a corresponding venous 
umbilical cord blood sample from birth. 
Of the 177 infants studied, 141 (80%) were term (37-41 completed weeks of 
gestation), 21 (12%) were near-term (35 or 36 weeks), and 15 (8%) had a gestational 
age of 32-34 weeks. Twenty-four (14%) infants were twins and three (2%) were 
triplets. Sixty-two (35%) of the 177 infants were delivered vaginally, including 17 
(10%) cases requiring instrumental support; 115 (65%) were delivered by caesarean 
section (C-section), including 40 (23%) cases of C-section with prior onset of labor 
after the presentation of acute fetal or maternal distress (also referred to as 
secondary C-section). The percentage of deliveries by C-section was significantly 
higher in preterm infants (31 of 36, 86%) than in term infants (83 of 141, 59%, 
p=0.003). For details see also Table 1. 
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Table 1: Selected characteristics of mothers and their infants 
 Venous plasma 
umbilical cord  
(n = 143) 
Arterial plasma 
umbilical cord  
(n = 117) 
Venous plasma 
day 3 
(n = 102) 
Characteristics n (%) n (%) n (%) 
Infant sex    
  Male 78 (55) 69 (59) 60 (59) 
Infant birth weight (g)    
  < 2000 11 (8) 6 (5) 8 (8) 
  2000 - 3000 47 (32) 38 (31) 26 (26) 
  3001 - 4000 77 (54) 66 (56) 61 (61) 
  > 4000 8 (6) 7 (6) 7 (7) 
Infant gestational age at birth   
(completed weeks) 
   
  Preterm 32 - 36 32 (22) 26 (22) 20 (20) 
  Term 37 - 41 111 (78) 91 (78) 82 (80) 
Mode of delivery    
  Caesarean section elective 74 (52) 63 (54) 42 (42) 
  Caesarean section with labor 26 (18) 23 (20) 21 (21) 
  Spontaneous vaginal 30 (21) 23 (20) 28 (28) 
  Instrumental vaginal 13 (9) 8 (7) 11 (11) 
 
 
The median copeptin concentration at birth was 18.2 pmol/L (range 2.38-5000 
pmol/L) in arterial cord blood and 10.2 pmol/L (range 1.87-5000 pmol/L) in venous 
cord blood. At day 3 of life, the median venous copeptin concentration was 13.5 
pmol/L (range 4.63-169 pmol/L). The difference in the average values of the paired 
umbilical cord samples was statistically significant (p<0.001). Furthermore, these 
paired sets of values were very strongly and significantly correlated with one another 
(Rs=0.825, p<0.001); when copeptin in the arterial cord blood sample increased, it 
regularly increased in the corresponding venous cord blood sample (Figure 3). No 
relationship could be determined with regards to the paired venous samples from 
birth and day 3 of life. 
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Figure 3: Correlation of copeptin concentrations in paired arterial and venous 
umbilical cord blood samples 
 
 
 
 
 
 
 
 
 
 
 
 
There was no significant gender difference in the average copeptin values in any of 
the three samples. As to gestational age there was a significant positive correlation 
with copeptin in both the umbilical artery and vein (Rs=0.377, Rs=0.416, both 
p<0.001, respectively), but none with copeptin at day 3 of life. Birth weight correlated 
weakly with copeptin concentrations in venous cord blood only (R=0.183, p=0.029). 
There was no correlation between the APGAR scores at 5 and 10 minutes or the 
hematocrit in umbilical cord blood and the copeptin concentrations in any plasma 
samples. 
There was a very significant inverse correlation between the pH value measured in 
umbilical artery blood and the copeptin concentrations in both arterial and venous 
cord blood (Rs=-0.639, Rs=-0.578, both p<0.001, respectively). At physiological pH 
values, copeptin levels remain under a certain threshold and then tend to increase as 
Correlation 0.825, p < 0.001 
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the pH decreases (Figure 4). Accordingly, there was also a very significant inverse 
correlation between umbilical artery base excess and the copeptin concentrations in 
both arterial and venous cord blood (Rs=-0.645, Rs=-0.638, both p<0.001, 
respectively). Contrarily, neither base excess nor pH correlated with copeptin 
concentrations measured in venous plasma at day 3 of life. 
 
Figure 4: Copeptin in umbilical artery blood in relation to arterial pH and 
delivery mode 
 
 
 
 
 
 
 
 
 
 
 
 
As to the mode of delivery, spontaneous and assisted vaginal deliveries were 
associated with much higher median copeptin concentrations in both arterial and 
venous cord plasma. In comparison, C-section, with or without prior onset of labor, 
was associated with lower copeptin values at birth (Table 2). The median copeptin 
concentrations at day 3 of life were similar in all groups regardless of delivery mode. 
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Table 2: Copeptin intervals in arterial (a) and venous (v) umbilical cord plasma 
 
 
Mode of delivery 
 
n 
a / v 
Median copeptin 
pmol/L 
a / v 
95% reference 
interval, pmol/L 
a / v 
 
Pa 
a / v 
Caesarean elective 63 / 73 8 / 5 3-907 / 5-504  
Caesarean with labor 23 / 27 14 / 11 4-2240 / 2-2260 < 0.01 / < 0.01 
Vaginal spontaneous 23 / 30 1610 / 644 82-5000 / 6-5000 < 0.001 / < 0.001 
Vaginal instrumental 8 / 13 1786 / 1324 1786-5000 / 90-4900 < 0.001 / < 0.001 
a Significance between caesarean primary and with each other mode of delivery; a, arterial; v, venous  
 
 
Concerning pregnancy and labor, there was a significant (p=0.003, p=0.001, 
respectively) difference in both arterial and venous umbilical cord plasma copeptin 
concentrations in the group of expectant mothers who had experienced a failure in 
progress of labor compared to those who did not. In the first group, average copeptin 
levels tended to be higher. The same was observed in the groups who had received 
synthetic oxytocin or prostaglandin E1 analogue administration during labor and in 
the group in which an epidural anesthesia was performed (p<0.001, throughout). In 
all of these subgroups, however, no significant difference was found in copeptin at 
day 3 of life. 
Finally, there was a very significant inverse correlation between maximal weight loss 
during postnatal adaptation and the copeptin concentrations in arterial as well as 
venous umbilical cord plasma at birth (Rs=-0.309, Rs=-0.289, both p=0.001, 
respectively). On the other hand, maximal postnatal weight loss correlated directly 
with the copeptin concentration in venous plasma drawn at day 3 of life (Rs=0.438, 
p<0.001). These correlations are illustrated in Figures 5 and 6. 
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Figure 5: Correlation of copeptin in 
venous umbilical cord plasma with 
maximal postnatal weight loss. Maximal 
postnatal weight loss is grouped in mild (2-5%, 
n=33), moderate (6-7%, n=51), and strong loss 
(8-12%, n=53). Data are presented as box 
(interquartile range) and whisker (5-95 % range) 
plots. 
Figure 6: Correlation of copeptin in 
venous plasma at day 3 with maximal 
postnatal weight loss. Maximal postnatal 
weight loss is grouped in mild (2-5%, n=29), 
moderate (6-7%, n=36), and strong loss (8-12%, 
n=37). Data are presented as box (interquartile 
range) and whisker (5-95 % range) plots.  
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5. Discussion  
 
In this study copeptin was measured for the first time in newborn infants. The aim of 
this study was to establish copeptin reference values for this group and to determine 
the effects of various perinatal factors on copeptin concentrations at birth and at day 
3 of life. The study was performed in a non hypothesis-driven manner. 
Copeptin in arterial umbilical cord plasma was consistently higher than in venous 
umbilical cord plasma. This supports the notion that the measured copeptin 
originates from the fetus and not from the mother. It was reported for anencephalic 
newborns that they did not have circulating AVP 59, clearly demonstrating that the 
human placental barrier is tight for AVP 60. 
Interestingly, there was a very large distribution of copeptin values at birth with 
maximum concentrations reaching the upper detection limit of the immunoassay 
(5000 pmol/L) in both sets of cord blood samples. This was not once the case in any 
of the plasma samples collected at day 3 of life, where the highest measured 
copeptin value amounted to 169 pmol/L. Hence, even maximum copeptin 
concentrations present at birth all returned to normal low levels by day 3 of life. 
The observations made in this study were in accordance with previous findings made 
for AVP, which at birth and especially after vaginal delivery can be present at very 
high plasma concentrations that decrease shortly afterwards to normal low levels 35–
37. Therefore, copeptin appears to accurately mirror AVP activity also at birth. One 
limitation to this study, however, was that AVP was not measured to prove any direct 
correlation between AVP and copeptin during early neonatal life. 
Birth is a stressful event for both mother and child, and AVP is known to be involved 
in the fetal stress response 36,61. In this study the same was observed for copeptin. 
Overall, the average copeptin values in umbilical cord plasma of neonates born 
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without any birth stress (elective C-section group) were within the range of normal 
copeptin values found in healthy adults (median 4.2 pmol/L, range 1-13.8 pmol/L 45). 
In contrast, in the presence of any birth stress, umbilical cord copeptin levels rose 
exceptionally. Vaginal delivery especially was associated with much higher birth 
copeptin levels, namely a 200-fold increase, as compared to C-section delivery, 
indicating a clear link to birth stress. This was furthermore supported by the strong 
relationships found between cord blood copeptin and established blood stress 
markers such as the pH value and base excess in umbilical artery blood. Average 
copeptin values at birth were even lower after elective C-section compared to after C-
section with prior onset of labor, hence the presence of contractions is important for 
copeptin release. It is well known that uterine contractions cause a transient 
decrease in maternal-fetal blood flow and subsequently a transient hypoxia in the 
fetus. The here presented data on copeptin release fitted to the previous findings that 
hypoxic stress triggers AVP release 62,63. 
Neither mode of delivery nor birth acidosis influenced copeptin concentrations in 
venous plasma drawn at day 3 of life. Moreover, there was no correlation between 
copeptin concentrations at birth and those at day 3 of life. These findings can be 
interpreted in two ways. First, once the posterior pituitary releases all of its stored 
AVP/copeptin, it requires a bit of time to replenish itself. This may be the case in 
infants with exceptionally high copeptin concentrations at birth and copeptin 
concentrations below the average at day 3 of life. In contrast to this hypothetical 
conclusion, a second interpretation is based on additional findings. The direct 
correlation between maximal postnatal weight loss and plasma copeptin 
concentrations at day 3 of life illustrated an appropriate AVP response to negative 
water balance, whereas infants with elevated copeptin concentrations at birth 
subsequently had a milder postnatal weight loss. Therefore, a second plausible 
 22 
conclusion is that AVP/copeptin can be released in extremely high amounts at birth 
and still the AVP system is able to function as it should, at least in the first few days 
of life. One could argue even that an increased stimulation of the AVP/copeptin 
system at birth is favorable for preventing dehydration in early neonatal life. Indeed, 
delayed voiding has been shown to be a function of high AVP levels at birth 64,65. 
Besides the effect of AVP on water balance, recent findings have indicated a central 
role of AVP-receptor signaling in peripheral analgesia 66. It was found that infants 
born by vaginal delivery have a natural analgesia within the first hours of life 
compared to those born by elective C-section 67. Keeping the here presented high 
levels of copeptin after vaginal delivery and the AVP-receptor signaling in peripheral 
analgesia in mind, one may arrive to the conclusion that an AVP/copeptin release at 
birth is mediating this 60. Until now many lecturers have accredited oxytocin a central 
role in birth analgesia, but AVP not oxytocin is increased at birth and it so appears 
that the AVP receptor is signaling peripheral analgesia 60. 
Respiratory morbidity is less frequent after C-section with prior onset of labor 
compared to after elective C-section, and even less frequent after vaginal delivery 68. 
The findings in this study showed a similar pattern, where higher copeptin values 
were found more frequently after C-section with prior onset of labor compared to after 
elective C-section, and even more frequently after vaginal birth. Therefore, 
adequately high AVP/copeptin concentrations at birth may provide a natural 
advantage in early pulmonary adaptation. In fact, activation of vasopressin receptors 
situated on type II pneumocytes and pulmonary vasculature endothelium results in 
surfactant secretion 69 and pulmonary vasodilation, especially under hypoxic 
conditions 70,71. 
Lastly, researchers now widely acknowledge an involvement of brain-located AVP in 
the modulation of complex social behaviors, including maternal behavior and bonding 
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72. Of course the effects on behavior vary from species to species 73. In rats, it has 
been demonstrated that increased AVP activity in certain areas of the brain promotes 
maternal care 74 and is characteristic of increased maternal aggression 75. Moreover, 
AVP is necessary in regulating selective partner preference in adult pair bond 
formation in prairie voles 76,77, although it remains unclear whether it prompts pair 
bonding between a mother and her offspring. Recent studies have begun to 
investigate a similar AVP-involvement also in human behavior 78–81; it is tempting to 
hypothesize that the surge of AVP/copeptin after normal delivery is favorable in early 
mother-child bonding. Nonetheless, queries concerning the interaction of peripheral 
and central AVP action remain unsolved: first, does AVP found in the circulation 
cross the blood-brain barrier at birth, even if only at very high concentrations? 
Second, if the blood-brain barrier is usually tight for AVP, does high AVP affect its 
permeability? Third, is there an increased neuronal AVP release in the brain in 
response to stress, for example vaginal delivery? The literature is surprisingly empty 
especially when searching for human data. Animal models may provide some of 
these answers, although caution in interpretation is appropriate 60. 
In conclusion, the results from copeptin research on adults praise its potential clinical 
use as a possible diagnostic and prognostic biomarker for illnesses ranging from 
cardiopulmonary disease to acute life-threatening situations to stroke 47. One could 
only expect to find a similar applicability in pediatric medicine. For example, in this 
study’s cohort no asphyxia was present, but colleagues in Bern have recently 
demonstrated that copeptin levels are consistently very high in cord blood drawn from 
asphyxiated infants at birth 82. With that in mind, copeptin should be considered as a 
potential marker for birth stress and particularly as a possible diagnostic tool for 
perinatal asphyxia. 
 
 24 
6. Bibliography 
 
1. Sofroniew MV, Weindl A, Schinko I, Wetzstein R. The distribution of vasopressin-, 
oxytocin-, and neurophysin-producing neurons in the guinea pig brain. I. The 
classical hypothalamo-neurophypophyseal system. Cell and tissue research. 
1979;196(3):367–84.  
2. Sofroniew MV. Morphology of vasopressin and oxytocin neurones and their central 
and vascular projections. Progress in brain research. 1983;60:101–14.  
3. Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential 
conformation shaping of neurohypophysial preprohormones during intraneuronal 
secretory transport. Journal of molecular neuroscience : MN. 2002;18(3):223–8.  
4. Roberts MM, Robinson AG, Hoffman GE, Fitzsimmons MD. Vasopressin transport 
regulation is coupled to the synthesis rate. Neuroendocrinology. 1991;53(4):416–22.  
5. Nowycky MC, Seward EP, Chernevskaya NI. Excitation-secretion coupling in 
mammalian neurohypophysial nerve terminals. Cellular and molecular neurobiology. 
1998;18(1):65–80.  
6. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from 
the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 
2005;26(12):2500–4.  
7. Zingg HH, Lefebvre D, Almazan G. Regulation of vasopressin gene expression in 
rat hypothalamic neurons. Response to osmotic stimulation. The Journal of biological 
chemistry. 1986;261(28):12956–9.  
8. Baumann G, Dingman JF. Distribution, blood transport, and degradation of 
antidiuretic hormone in man. The Journal of clinical investigation. 1976;57(5):1109–
16.  
9. Solis-Herruzo JA, Gonzalez-Gamarra A, Castellano G, Muñoz-Yagüe MT. 
Metabolic clearance rate of arginine vasopressin in patients with cirrhosis. 
Hepatology (Baltimore, Md.). 1992;16(4):974–9.  
10. Johnson AK, Thunhorst RL. The neuroendocrinology of thirst and salt appetite: 
visceral sensory signals and mechanisms of central integration. Frontiers in 
neuroendocrinology. 1997;18(3):292–353.  
11. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application 
of a new method for the radioimmunoassay of arginine vasopressin in human 
plasma. The Journal of clinical investigation. 1973;52(9):2340–52.  
12. Thrasher TN. Baroreceptor regulation of vasopressin and renin secretion: low-
pressure versus high-pressure receptors. Frontiers in neuroendocrinology. 
1994;15(2):157–96.  
 25 
13. Rowe JW, Shelton RL, Helderman JH, Vestal RE, Robertson GL. Influence of the 
emetic reflex on vasopressin release in man. Kidney international. 1979;16(6):729–
35.  
14. Baylis PH, Zerbe RL, Robertson GL. Arginine vasopressin response to insulin-
induced hypoglycemia in man. The Journal of clinical endocrinology and metabolism. 
1981;53(5):935–40.  
15. Zingg HH. Vasopressin and oxytocin receptors. Baillière’s clinical endocrinology 
and metabolism. 1996;10(1):75–96.  
16. Bartanusz V, Jezova D, Bertini LT, et al. Stress-induced increase in vasopressin 
and corticotropin-releasing factor expression in hypophysiotrophic paraventricular 
neurons. Endocrinology. 1993;132(2):895–902.  
17. Lolait SJ, Stewart LQ, Jessop DS, Young WS, O’Carroll A-M. The hypothalamic-
pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b 
receptors. Endocrinology. 2007;148(2):849–56.  
18. Ostrowski NL, Lolait SJ, Bradley DJ, et al. Distribution of V1a and V2 vasopressin 
receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. 
Endocrinology. 1992;131(1):533–5.  
19. Hernando F, Schoots O, Lolait SJ, Burbach JP. Immunohistochemical localization 
of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical 
support for its involvement in the central effects of vasopressin. Endocrinology. 
2001;142(4):1659–68.  
20. de Wied D, Diamant M, Fodor M. Central nervous system effects of the 
neurohypophyseal hormones and related peptides. Frontiers in neuroendocrinology. 
1993;14(4):251–302.  
21. Moore K, Thompson C, Trainer P. Disorders of water balance. Clinical medicine 
(London, England). 2003;3(1):28–33.  
22. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic 
shock. Critical care medicine. 2003;31(6):1752–8.  
23. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to 
the vasodilation of septic shock. Circulation. 1997;95(5):1122–5.  
24. Malay MB, Ashton RC, Landry DW, Townsend RN. Low-dose vasopressin in the 
treatment of vasodilatory septic shock. The Journal of trauma. 1999;47(4):699–703; 
discussion 703–5.  
25. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects 
of low-dose vasopressin infusions in vasodilatory septic shock. Critical care medicine. 
2001;29(3):487–93.  
26. Lindner KH, Prengel AW, Brinkmann A, et al. Vasopressin administration in 
refractory cardiac arrest. Annals of internal medicine. 1996;124(12):1061–4.  
 26 
27. Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and 
epinephrine for out-of-hospital cardiopulmonary resuscitation. The New England 
journal of medicine. 2004;350(2):105–13.  
28. Valania G, Singh M, Slawsky MT. Targeting hyponatremia and hemodynamics in 
acute decompensated heart failure: is there a role for vasopressin antagonists? 
Current heart failure reports. 2011;8(3):198–205.  
29. Wagener G, Kovalevskaya G, Minhaz M, et al. Vasopressin deficiency and 
vasodilatory state in end-stage liver disease. Journal of cardiothoracic and vascular 
anesthesia. 2011;25(4):665–70.  
30. Murayama K, Meeker RB, Murayama S, Greenwood RS. Developmental 
expression of vasopressin in the human hypothalamus: double-labeling with in situ 
hybridization and immunocytochemistry. Pediatric research. 1993;33(2):152–8.  
31. Burford GD, Robinson IC. Oxytocin, vasopressin and neurophysins in the 
hypothalamo-neurohypophysial system of the human fetus. The Journal of 
endocrinology. 1982;95(3):403–8.  
32. Reppert SM, Uhl GR. The vasopressin gene is expressed prior to regulation in 
the supraoptic nuclei of fetal rats. Brain research. 1988;456(2):392–6.  
33. Abramova MA, Ugryumov MV, Kalas A. Vasopressinergic neurons in rats in 
ontogenesis: responses to salt loading and their modulation by noradrenergic 
afferents. Neuroscience and behavioral physiology. 2008;38(6):605–11.  
34. Tsukahara H, Sekine K, Miura M, et al. Vasoactive and natriuretic mediators in 
umbilical cord blood: a report of our observation and review of the literature. Early 
human development. 2002;69(1-2):57–64.  
35. Pohjavuori M, Raivio KO. The effects of acute and chronic perinatal stress on 
plasma vasopressin concentration and renin activity at birth. Biology of the neonate. 
1985;47(5):259–64.  
36. Pohjavuori M, Fyhrquist F. Vasopressin, ACTH and neonatal haemodynamics. 
Acta paediatrica Scandinavica. Supplement. 1983;305:79–83.  
37. Rascher W, Rauh W, Brandeis WE, Huber KH, Schärer K. Determinants of 
plasma arginine-vasopressin in children. Acta paediatrica Scandinavica. 
1986;75(1):111–7.  
38. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved 
extraction procedure and RIA for determination of arginine8-vasopressin in plasma: 
role of premeasurement sample treatment and reference values in children. Clinical 
chemistry. 1999;45(1):98–103.  
39. Lodha R, Vivekanandhan S, Sarthi M, Kabra SK. Serial circulating vasopressin 
levels in children with septic shock. Pediatric critical care medicine : a journal of the 
Society of Critical Care Medicine and the World Federation of Pediatric Intensive and 
Critical Care Societies. 2006;7(3):220–4.  
 27 
40. Rodríguez-Núñez A, López-Herce J, Gil-Antón J, Hernández A, Rey C. Rescue 
treatment with terlipressin in children with refractory septic shock: a clinical study. 
Critical care (London, England). 2006;10(1):R20.  
41. Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in 
children with vasodilatory shock after cardiac surgery. Circulation. 1999;100(19 
Suppl):II182–6.  
42. Matok I, Rubinshtein M, Levy A, et al. Terlipressin for children with extremely low 
cardiac output after open heart surgery. The Annals of pharmacotherapy. 
2009;43(3):423–9.  
43. Gil-Antón J, López-Herce J, Morteruel E, Carrillo A, Rodríguez-Núñez A. 
Pediatric cardiac arrest refractory to advanced life support: is there a role for 
terlipressin? Pediatric critical care medicine : a journal of the Society of Critical Care 
Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 
2010;11(1):139–41.  
44. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet 
vasopressin in essential hypertension and congestive heart failure. Hypertension. 
1983;5(2 Pt 2):I129–38.  
45. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement 
of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical 
chemistry. 2006;52(1):112–9.  
46. Barat C, Simpson L, Breslow E. Properties of human vasopressin precursor 
constructs: inefficient monomer folding in the absence of copeptin as a potential 
contributor to diabetes insipidus. Biochemistry. 2004;43(25):8191–203.  
47. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a 
new biomarker. Trends in endocrinology and metabolism: TEM. 2008;19(2):43–9.  
48. Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the c-
terminal portion of arginine vasopressin during water deprivation and excess in 
healthy subjects. The Journal of clinical endocrinology and metabolism. 
2007;92(10):3973–8.  
49. Morgenthaler NG, Müller B, Struck J, et al. Copeptin, a stable peptide of the 
arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 
(Augusta, Ga.). 2007;28(2):219–26.  
50. Katan M, Morgenthaler NG, Dixit KCS, et al. Anterior and posterior pituitary 
function testing with simultaneous insulin tolerance test and a novel copeptin assay. 
The Journal of clinical endocrinology and metabolism. 2007;92(7):2640–3.  
51. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine 
vasopressin concentrations in critically ill patients. The Journal of clinical 
endocrinology and metabolism. 2006;91(11):4381–6.  
 28 
52. Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (copeptin) as 
a novel and prognostic marker in acute myocardial infarction: Leicester Acute 
Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115(16):2103–10.  
53. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute 
myocardial infarction. Journal of the American College of Cardiology. 
2010;55(19):2096–106.  
54. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) 
is a strong prognostic marker in patients with heart failure after an acute myocardial 
infarction: results from the OPTIMAAL study. European heart journal. 
2009;30(10):1187–94.  
55. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel 
biomarker, in lower respiratory tract infections. European journal of clinical 
investigation. 2007;37(2):145–52.  
56. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and 
procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 
2007;131(4):1058–67.  
57. Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and 
outcome in patients with acute intracerebral hemorrhage. BMC neurology. 
2010;10:34.  
58. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: one-year 
outcome in patients with acute stroke. Stroke; a journal of cerebral circulation. 
2010;41(7):1564–7.  
59. Chard T, Hudson CN, Edwards CR, Boyd NR. Release of oxytocin and 
vasopressin by the human foetus during labour. Nature. 1971;234(5328):352–4.  
60. Wellmann S, Bührer C. Who plays the strings in newborn analgesia at birth, 
vasopressin or oxytocin? Frontiers in neuroscience. 2012;6:78.  
61. Ramin SM, Porter JC, Gilstrap LC, Rosenfeld CR. Stress hormones and acid-
base status of human fetuses at delivery. The Journal of clinical endocrinology and 
metabolism. 1991;73(1):182–6.  
62. Speer ME, Gorman WA, Kaplan SL, Rudolph AJ. Elevation of plasma 
concentrations of arginine vasopressin following perinatal asphyxia. Acta paediatrica 
Scandinavica. 1984;73(5):610–4.  
63. Ruth V, Fyhrquist F, Clemons G, Raivio KO. Cord plasma vasopressin, 
erythropoietin, and hypoxanthine as indices of asphyxia at birth. Pediatric research. 
1988;24(4):490–4.  
64. Vuohelainen T, Ojala R, Virtanen A, et al. Predictors of AVP and TSH levels and 
the timing of first voiding in the newborn. Pediatric research. 2007;62(1):106–10.  
 29 
65. Vuohelainen T, Ojala R, Virtanen A, Holm P, Tammela O. Predictors of delayed 
first voiding in newborn. Acta paediatrica (Oslo, Norway : 1992). 2008;97(7):904–8.  
66. Schorscher-Petcu A, Sotocinal S, Ciura S, et al. Oxytocin-induced analgesia and 
scratching are mediated by the vasopressin-1A receptor in the mouse. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2010;30(24):8274–
84.  
67. Bergqvist LL, Katz-Salamon M, Hertegård S, Anand KJS, Lagercrantz H. Mode of 
delivery modulates physiological and behavioral responses to neonatal pain. Journal 
of perinatology : official journal of the California Perinatal Association. 2009;29(1):44–
50.  
68. Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of 
delivery at term: influence of timing of elective caesarean section. British journal of 
obstetrics and gynaecology. 1995;102(2):101–6.  
69. Brown LA, Chen M. Vasopressin signal transduction in rat type II pneumocytes. 
The American journal of physiology. 1990;258(6 Pt 1):L301–7.  
70. Walker BR, Haynes J, Wang HL, Voelkel NF. Vasopressin-induced pulmonary 
vasodilation in rats. The American journal of physiology. 1989;257(2 Pt 2):H415–22.  
71. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-
dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production 
of nitric oxide. Chest. 1993;103(4):1241–5.  
72. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of 
sociality. Science (New York, N.Y.). 2008;322(5903):900–4.  
73. Insel TR, Young LJ. Neuropeptides and the evolution of social behavior. Current 
opinion in neurobiology. 2000;10(6):784–9.  
74. Bosch OJ, Neumann ID. Brain vasopressin is an important regulator of maternal 
behavior independent of dams’ trait anxiety. Proceedings of the National Academy of 
Sciences of the United States of America. 2008;105(44):17139–44.  
75. Bosch OJ, Neumann ID. Vasopressin released within the central amygdala 
promotes maternal aggression. The European journal of neuroscience. 
2010;31(5):883–91.  
76. Winslow JT, Hastings N, Carter CS, Harbaugh CR, Insel TR. A role for central 
vasopressin in pair bonding in monogamous prairie voles. Nature. 
1993;365(6446):545–8.  
77. Cho MM, DeVries AC, Williams JR, Carter CS. The effects of oxytocin and 
vasopressin on partner preferences in male and female prairie voles (Microtus 
ochrogaster). Behavioral neuroscience. 1999;113(5):1071–9.  
78. Walum H, Westberg L, Henningsson S, et al. Genetic variation in the vasopressin 
receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. 
 30 
Proceedings of the National Academy of Sciences of the United States of America. 
2008;105(37):14153–6.  
79. Kim S-J, Young LJ, Gonen D, et al. Transmission disequilibrium testing of 
arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Molecular 
psychiatry. 2002;7(5):503–7.  
80. Wassink TH, Piven J, Vieland VJ, et al. Examination of AVPR1a as an autism 
susceptibility gene. Molecular psychiatry. 2004;9(10):968–72.  
81. Yirmiya N, Rosenberg C, Levi S, et al. Association between the arginine 
vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: 
mediation by socialization skills. Molecular psychiatry. 2006;11(5):488–94.  
82. Schlapbach LJ, Frey S, Bigler S, et al. Copeptin concentration in cord blood in 
infants with early-onset sepsis, chorioamnionitis and perinatal asphyxia. BMC 
pediatrics. 2011;11:38.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31 
7. Acknowledgements 
 
My deepest thanks go to Dr. Sven Wellmann, whose time and assistance I sincerely 
appreciate. I would also like to thank the Department of Neonatology, the Department 
of Obstetrics and especially Prof. Hans Ulrich Bucher of Zurich University Hospital for 
making this study possible, as well as my family for their constant support throughout 
my studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
8. Curriculum Vitae 
 
Giuditta Barbara Cippà of Bellinzona TI 
27.07.1987  Born in Zurich ZH 
1993 – 1997  Bells Mill Elementary School, Potomac MD (USA) 
1997 – 2002  The Bullis School, Potomac MD (USA) 
2002 – 2005  Zurich International School, Kilchberg ZH  
2005   International Baccalaureate Diploma 
2005 – 2006  Studies of Biology, University of Zurich, Zurich ZH 
2006 – 2012  Studies of Human Medicine, University of Zurich, Zurich ZH 
2012   State Medical Examination, University of Zurich, Zurich ZH 
2013   Resident physician, Department of Anesthesiology and Intensive-
   Care Medicine, Kantonsspital Schaffhausen, Schaffhausen SH 
 
Since 2014 Resident physician, Department of Neonatology, Zurich 
University Hospital, Zurich ZH 
   
  
 
 
 
 
 
 
 33 
